Article: Developer Can’t Revive Lloyds Suit Over Misselling Review

Article - Media, Publications

Developer Can’t Revive Lloyds Suit Over Misselling Review

Paige Long, 16 April 2021

An English appeals court ruled on Friday that a property investor cannot sue Lloyds Banking Group over its conduct during a review of interest rate hedging products bought in the mid-2000s because his complaint was invalid.

The Court of Appeal upheld a decision from July that threw out the lawsuit brought by Clive Davis against Lloyds Bank. The higher court ruled that the property investor’s grievances did not comply with the regulatory definition of “complaint” in the Financial Conduct Authority’s dispute resolution rules. Continue reading “Article: Developer Can’t Revive Lloyds Suit Over Misselling Review”

Article: InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

Article - Media, Publications

InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

PRNewswire, 19 January 2021

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe (“CDP Europe”). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg – Vice President, Chemistry, Manufacturing & Controls, Karen Long – Senior Director, Drug Development, and Prof. Mauro Maccarrone PhD – Scientific Advisor to InMed will all be featured as expert speakers at the event.

Read Full Article

Article: The Emperor is Naked: David Stockman

Article - Media

The Emperor is Naked: David Stockman

Karen Roche, JT Long

The Gold Report cited by NASDAQ.com, 4 May 2012

A “paralyzed” Federal Reserve Bank, in its “final days,” held hostage by Wall Street “robots” trading in markets that are “artificially medicated” are just a few of the bleak observations shared by David Stockman, former Republican U.S. Congressman and director of the Office of Management and Budget. He is also a founding partner of Heartland Industrial Partners and the author of The Triumph of Politics: Why Reagan’s Revolution Failed and the soon-to-be released The Great Deformation: How Crony Capitalism Corrupts Free Markets and Democracy.The Gold Report caught up with Stockman for this exclusive interview at the recent Recovery Reality Check conference.

Read full article.